Aggregation of β-amyloid peptide is promoted by membrane phospholipid metabolites elevated in Alzheimer's disease brain

Journal of Neurochemistry

Volumn 69, Issue 1, 1997, Pages 266-272

  Klunk, William E ^a   Xu, Chong Jun ^a   McClure, Richard J ^a   Panchalingam, Kanagasabai ^a   Stanley, Jeff A ^a   Pettegrew, Jay W ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Aggregation; Alzheimer's disease; Glycerophosphocholine; Phosphodiester; Phosphomonoester; Amyloid peptide

Indexed keywords

AMYLOID BETA PROTEIN; GLYCEROPHOSPHORYLCHOLINE; MEMBRANE PHOSPHOLIPID;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; PATHOPHYSIOLOGY; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROTEIN AGGREGATION; TRANSMISSION ELECTRON MICROSCOPY;

EID: 0031005995     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1997.69010266.x     Document Type: Article

References (52)

1. Behl C., Davis J., Cole G. M., and Schubert D. (1992) Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem. Biophys. Res. Commun. 186, 944-950.
2. Castano E. M., Ghiso J., Prelli F., Gorevic P. D., Migheli A., and Frangione B. (1986) In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer's disease beta-protein. Biochem. Biophys. Res. Commun. 141, 782-789.
3. Ellison D. W., Beal M. F., and Martin J. B. (1987) Phosphoethanolamine and ethanolamine are decreased in Alzheimer's disease and Huntington's disease. Brain Res. 417, 389-392.
4. Esch F. S., Keim P. S., Beattie E. C., Blacher R. W., Culwell A. R., Oltersdorf T., McClure D., and Ward P. J. (1990) Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 248, 1122-1124.
5. Esler W. P., Stimson E. R., Ghilardi J. R., Vinters H. V., Lee J. P., Mantyh P. W., and Maggio J. E. (1996) In vitro growth of Alzheimer's disease beta-amyloid plaques displays first-order kinetics. Biochemistry 35, 749-757.
6. Evans K. C., Berger E. P., Cho C. G., Weisgraber K. H., and Lansbury P. T. Jr. (1995) Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc. Natl. Acad. Sci. USA 92, 763-767.
7. Fraser P. E., Nguyen J. T., Surewicz W. K., and Kirschner D. A. (1991) pH-dependent structural transitions of Alzheimer amyloid peptides. Biophys. J. 60, 1190-1201.
8. Giordano T., Pan J. B., Monteggia L. M., Holzman T. F., Snyder S. W., Krafft G., Ghanbari H., and Kowall N. W. (1994) Similarities between beta amyloid peptides 1-40 and 40-1: effects on aggregation, toxicity in vitro, and injection in young and aged rats. Exp. Neurol. 125, 175-182.
9. Goedert M. (1993) Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci. 16, 460-465.
10. Gorevic P. D., Castano E. M., Sarma R., and Frangione B. (1987) Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic x-ray diffraction pattern. Biochem. Biophys. Res. Commun. 147, 854-862.
11. Haass C., Schlossmacher M. G., Hung A. Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B. L., Lieberburg I., Koo E. H., Schenk D., Teplow D. B., and Selkoe D. I. (1992) Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359, 322-325.
12. Halverson K., Fraser P. E., Kirschner D. A., and Lansbury P. T. Jr. (1990) Molecular determinants of amyloid deposition in Alzheimer's disease: conformational studies of synthetic beta-protein fragments. Biochemistry 29, 2639-2644.
13. Hilbich C., Kisters-Woike B., Reed I., Masters C., and Beyreuther K. (1991) Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease. J. Mol. Biol. 218, 149-163.
14. Hilbich C., Kisters-Woike B., Reed J., Masters C. L., and Beyreuther K. (1992) Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. J. Mol. Biol. 228, 460-473.
15. Hewlett D. R., Jennings K. H., Lee D. C., Clark M. S., Brown F., Wetzel R., Wood S. J., Camilleri P., and Roberts G. W. (1995) Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration 4, 23-32.
16. Jarrett J. T. and Lansbury P. T. Jr. (1992) Amyloid fibril formation requires a chemically discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial protein OsmB. Biochemistry 31, 12345-12352.
17. Jarrett J. T. and Lansbury P. T. Jr. (1993) Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058.
18. Jarrett J. T., Berger E. P., and Lansbury P. T. Jr. (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693-4697.
19. Joachim C. L., Morris J. H., and Selkoe D. J. (1988) Clinically diagnosed Alzheimer's disease: autopsy results in 150 cases. Ann. Neurol. 24, 50-56.
20. Kirschner D. A., Abraham C., and Selkoe D. J. (1986) X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation. Proc. Natl. Acad. Sci. USA 83, 503-507.
21. Kirschner D. A., Inouye H., Duffy L. K., Sinclair A., Lind M., and Selkoe D. J. (1987) Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro. Proc. Natl. Acad. Sci. USA 84, 6953-6957.
22. 31P MRS of PCA extracts of post-mortem Alzheimer's disease brain. Neurobiol. Aging 17, 349-357.
23. Lomakin A., Chung D. S., Benedek G. B., Kirschner D. A., and Teplow D. B. (1996) On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants. Proc. Natl. Acad. Sci. USA 96, 1125-1129.
24. Lorenzo A. and Yankner B. A. (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. USA 91, 12243-12247.
25. Mann D. M. A. (1985) The neuropathology of Alzheimer's disease: a review with pathogenetic, aetiological and therapeutic considerations. Mech. Ageing Dev. 31, 213-255.
26. Mattson M. P., Cheng B., Davis D., Bryant K., Lieberburg I., and Rydel R. E. (1992) Beta-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12, 376-389.
27. Mattson M. P., Tomaselli K. J., and Rydel R. E. (1993) Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF. Brain Res. 621, 35-49.
28. McClure R. J., Kanfer J. N., Panchalingam K., Klunk W. E., and Pettegrew J. W. (1995a) Magnetic resonance spectroscopy and its application to aging and Alzheimer's disease, in Neuroimaging Clinics of North America (George A., ed), pp. 69-85. W. B. Saunders, Philadelphia.
29. 31P MRS in vitro study of graded hypoxia in Fischer 344 rats. Soc. Neurosci. Abstr. 21, 2004.
30. Miyakawa T., Katsuragi S., Watanabe K., Shimoji A., and Ikeuchi Y. (1986) Ultrastructural studies of amyloid fibrils and senile plaques in human brain. Acta Neuropathol. (Berl.) 70, 202-208.
31. Mori H., Takio K., Ogawara M., and Selkoe D. J. (1992) Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J. Biol. Chem. 267, 17082-17086.
32. Nitsch R. M., Blusztajn J. K., Pittas A. G., Slack B. E., Growdon J. H., and Wurtman R. J. (1992) Evidence for a membrane defect in Alzheimer disease brain. Proc. Natl. Acad. Sci. USA 89, 1671-1675.
33. 31P in vivo NMR spectroscopy. Soc. Neurosci. Abstr. 16, 843.
34. 31P nuclear magnetic resonance study of the brain in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 47, 235-248.
35. 31P NMR. Magn. Reson. Imaging 6, 135-142.
36. Pettegrew J. W., Panchalingam K., Withers G., McKeag D., and Strychor S. (1990) Changes in brain energy and phospholipid metabolism during development and aging in the Fischer 344 rat. J. Neuropathol. Exp. Neurol. 49, 237-249.
37. Pike C. J., Walencewicz A. J., Glabe C. G., and Cotman C. W. (1991) In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563, 311-314.
38. Pike C. J., Burdick D., Walencewicz A. J., Glabe C. G., and Cotman C. W. (1993) Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13, 1676-1687.
39. Pike C. J., Walencewicz-Wasserman A. J., Kosmoski J., Cribbs D. H., Glabe C. G., and Cotman C. W. (1995) Structure-activity analyses of β-amyloid peptides: contributions of the β25-35 region to aggregation and neurotoxicity. J. Neurochem. 64, 253-265.
40. Prelli F., Castano E., Glenner G. G., and Frangione B. (1988) Differences between vascular and plaque core amyloid in Alzheimer's disease. J. Neurochem. 51, 648-651.
41. Roher A., Wolfe D., Palutke M., and KuKuruga D. (1986) Purification, ultrastructure, and chemical analysis of Alzheimer disease amyloid plaque core protein. Proc. Natl. Acad. Sci. USA 83, 2662-2666.
42. Seelig J., Lehrmann R., and Terzi E. (1995) Domain formation induced by lipid-ion and lipid-peptide interactions. Mol. Membr. Biol. 12, 51-57.
43. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., Swindlehurst C., McCormack R., Wolfert R., Selkoe D., Lieberburg I., and Schenk D. (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359, 325-327.
44. Shen C. L., and Murphy R. M. (1995) Solvent effects on self-assembly of beta-amyloid peptide. Biophys. J. 95, 640-651.
45. Shen C. L., Fitzgerald M. C., and Murphy R. M. (1994) Effect of acid predissolution on fibril size and fibril flexibility of synthetic beta-amyloid peptide. Biophys. J. 67, 1238-1246.
46. Shoji M., Golde T. E., Ghiso J., Cheung T. T., Estus S., Shaffer L. M., Cai X. D., McKay D. M., Tintner R., Frangione B., and Younkin S. G. (1992) Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258, 126-129.
47. Sisodia S. S. (1992) Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc. Natl. Acad. Sci. USA 89, 6075-6079.
48. 31P magnetic resonance spectroscopy in Alzheimer's and Pick's disease. Neurobiol. Aging 14, 85-92.
49. Wardle C. A. and Riemersma R. A. (1994) Hypoxia-stimulated glycerol production from the isolated, perfused rat heart is mediated by non-adrenergic mechanisms. Basic Res. Cardiol. 89, 29-38.
50. Wood S. J., Wetzel R., Martin J. D., and Hurle M. R. (1995) Prolines and amyloidogenicity in fragments of the Alzheimer's peptide beta/A4. Biochemistry 34, 724-730.
51. Wu E., Lipton R. B., and Dickson D. W. (1992) Amyloid angiopathy in diffuse Lewy body disease. Neurology 42, 2131-2135.
52. Yankner B. A., Duffy L. K., and Kirschner D. A. (1990) Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250, 279-282.